READOUT 03 / DOSE-RESPONSE / 25 nmol/kg
DSIP dosage, as studied: doses, routes, and the short half-life.
What was given, to which species, by which route. No protocol. No human dose.
The short version
This page describes DSIP dosage the way the studies describe it — what researchers gave to animals and to a few human volunteers, by which route. It is not a guide. There is no recommended dose, no protocol, and nothing for sale here, because there is no approved product and no validated human dosing. Two facts matter most. First, DSIP clears the blood in minutes in animals — extremely fast [3]. Second, the dose-response is parabolic, meaning effect rises and then falls: a middle dose can beat a high one, so "more" is not "stronger" [3]. The most common human research dose was a single intravenous 25 nmol/kg [2]. Everything below is research context, in plain numbers, third person only.
DSIP dosage by species and route
DSIP dosage across the literature spans species, routes, and units that don't reduce to one number. The most frequently used human research dose was 25 nmol/kg, intravenous [2]. Rat growth-hormone studies used 0.1-10 micrograms infused into the brain, with a minimal effective dose around 0.1 microgram. Rat neuroprotection used 120 micrograms/kg. Mouse longevity (the Deltaran preparation) used about 100 micrograms/kg subcutaneously, five consecutive days monthly [5]. Cat sleep studies used 120 nmol/kg subcutaneously. Rat anticonvulsant work used 0.1-1 mg/kg, most effective at 1 mg/kg. These are study parameters, not instructions, and most are animal models.
DSIP peptide dosage and the parabolic curve
Interpreting DSIP peptide dosage is complicated by an unusual feature: a non-monotonic, parabolic dose-response, where effect climbs to a peak and then declines [3]. Higher doses are not reliably more effective than intermediate ones. Combined with an unidentified mechanism, this means dose conclusions from one model do not transfer cleanly to another [3]. The literature reports doses; it does not establish an optimal one for people, and no human dosing standard exists.
Half-life and clearance
DSIP is cleared fast. An enzyme-immunoassay study in dogs, monkeys, and rats reported plasma half-lives on the order of only a few minutes, attributed to rapid breakdown by aminopeptidases and plasma proteins. No validated human pharmacokinetic profile exists. The naturally phosphorylated form (DSIP-P) and some synthetic analogs are reported as more stable or potent in certain assays — part of why analogs, not native DSIP, often show the clearest effects [3].
DSIP peptide nasal spray and other routes
A DSIP peptide nasal spray is one delivery format discussed in the community, but the documented research routes are intravenous (human and animal), intracerebroventricular (into the brain, in rodents), subcutaneous (cat, mouse), intranasal (rat neuroprotection at 120 micrograms/kg), and in-vitro perifusion. Lyophilized research peptide is typically reconstituted in sterile or bacteriostatic water for laboratory use. No pharmaceutical-grade product, formulation, or stability standard exists for any route.